Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Hawthorne, New York 10532


Purpose:

Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis


Study summary:

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis


Criteria:

Inclusion Criteria: - male and non-pregnant females, age 6 months or older, with a confirmed diagnosis of moderate to severe atopic dermatitis (AD) Exclusion Criteria: - Lacks stable diagnosis of atopic dermatitis or has been diagnosed with mild atopic dermatitis.


NCT ID:

NCT02595073


Primary Contact:

Study Chair
Novum Pharmaceutical Research Services
http://www.novumprs.com/contact


Backup Contact:

N/A


Location Contact:

Hawthorne, New York 10532
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.